{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "McKinsey & Co", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Stocks and Bonds", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/30/business/dealbook/explaining-valeant-the-main-theories.html", "document_type": "article", "byline": {"person": [{"middlename": "Davidoff", "firstname": "Steven", "role": "reported", "rank": 1, "lastname": "SOLOMON", "organization": ""}], "original": "By STEVEN DAVIDOFF SOLOMON"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbWide.jpg", "legacy": {"wide": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg", "xlargeheight": "608", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 608}, {"url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1271", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Reasons given for the turmoil at Valeant Pharmaceuticals include its cuts in research and development, its drug pricing and investors\u2019 influence.", "pub_date": "2016-03-30T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "Deal Professor", "print_headline": "Explaining Valeant: The Main Theories", "main": "Explaining Valeant: The Main Theories", "content_kicker": "Deal Professor"}, "print_page": "5", "snippet": "Reasons given for the turmoil at Valeant Pharmaceuticals include its cuts in research and development, its drug pricing and investors\u2019 influence.", "_id": "56fb020f38f0d816b6b7e254", "slideshow_credits": null, "abstract": "Steven Davidoff Solomon Deal Professor column runs through various explanations for turmoil at Valeant Pharmaceuticals International, once Wall Street darling."}